HEAR评分识别低危胸痛的性能:系统评价与荟萃分析
该系统评价与荟萃分析纳入10项研究、33843例急性胸痛患者,评估HEAR评分(无肌钙蛋白的四项之和)在急诊和院前识别低危胸痛(急性冠脉综合征或主要不良心脏事件)的性能。急诊HEAR<2、<3、<4的敏感性分别为99.03%、97.54%、91.80%,阴性预测值分别为99.84%、99.75%、99.57%;HEAR<2的阴性似然比为0.07。院前HEAR<4的敏感性和阴性预测值分别为85.01%和91.48%。作者认为急诊HEAR<2可用于早期离院策略,院前场景目前不能推荐。
要点
- 急诊HEAR<2识别急性冠脉综合征或主要不良心脏事件的敏感性99.03%(95%CI 98.29-99.77),阴性预测值99.84%(95%CI 99.72-99.95)。
- 急诊HEAR<2的阴性似然比0.07(95%CI 0.02-0.12)。
- 急诊HEAR<3敏感性97.54%(95%CI 94.50-100)、阴性预测值99.75%(95%CI 99.65-99.85);HEAR<4敏感性91.80%(95%CI 84.62-98.98)、阴性预测值99.57%(95%CI 99.11-100)。
- 院前HEAR<4的合并敏感性85.01%(95%CI 80.56-89.47)、阴性预测值91.48%(95%CI 87.10-95.87),目前不能推荐用于院前。
- 作者结论:急诊HEAR<2可用于早期离院策略。
适用人群与场景
- 急诊及院前场景的急性胸痛患者;纳入英文的HEAR评分性能研究,数据无法获取者被排除。
诊断标准与关键阈值
- HEAR评分<2、<3、<4为急诊评估 cutoff;院前评估采用HEAR<4 cutoff。
研究设计与关键结果
- 系统评价与荟萃分析,纳入10项研究、33843例患者;其中3项为院前研究、3项为回顾性研究;研究偏倚风险为低至中等。
- 急诊HEAR<2敏感性99.03%(95%CI 98.29-99.77),阴性预测值99.84%(95%CI 99.72-99.95),阴性似然比0.07(95%CI 0.02-0.12)。
- 急诊HEAR<3敏感性97.54%(95%CI 94.50-100),阴性预测值99.75%(95%CI 99.65-99.85)。
- 急诊HEAR<4敏感性91.80%(95%CI 84.62-98.98),阴性预测值99.57%(95%CI 99.11-100)。
- 院前HEAR<4敏感性85.01%(95%CI 80.56-89.47),阴性预测值91.48%(95%CI 87.10-95.87)。
- 检索MEDLINE、Embase、Evidence-Based Medicine Reviews、Scopus和Web of Science,时间1946年至2021年7月;采用Quality Assessment of Diagnostic Accuracy Studies version 2评估质量;逆方差法和随机效应模型合并。
证据类型、等级与局限
- 研究类型:系统评价与荟萃分析;研究偏倚风险为低至中等。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为急诊HEAR<2可用于早期离院策略。
- 作者认为目前不能推荐HEAR评分用于院前场景。
指南或共识出处
- PROSPERO注册号CRD42021273710。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Chest pain is one of the most common presentations to the emergency department (ED) and HEART score (history, ECG, age, risk factors, and cardiac troponin) is recommended for risk stratification. It has been proposed that the sum of four items with no troponin (HEAR score) below 2 can be used safely to lower testing and reduce length of stay. To assess the performance of the HEAR score in hospital and prehospital settings, we performed a systematic review and meta-analysis. English studies on the performance of the HEAR score in patients with acute chest pain were included. They were excluded if data are inaccessible. MEDLINE, Embase, Evidence-Based Medicine Reviews, Scopus, and web of science were searched from 1946 to July 2021. The quality of studies was assessed using Quality Assessment of Diagnostic Accuracy Studies version 2. Acute coronary syndrome or major adverse cardiac events prediction were outcomes of interest. The performance indices with 95% confidence intervals (CIs) were extracted. Inverse variance and the random-effects model were used to report the results. Of the 692 articles on the HEAR score, 10 studies were included in the analysis with 33 843 patients. Studies were at low to moderate risk of bias. Three studies were in prehospital and three were retrospective. The pooling of data on the HEAR score showed that the sensitivity at the HEAR<2, <3, and <4 cutoffs in the ED were 99.03% (95% CI, 98.29-99.77), 97.54% (95% CI, 94.50-100), and 91.80% (95% CI, 84.62-98.98), respectively. The negative predictive values (NPVs) for the above cutoffs were 99.84% (95% CI, 99.72-99.95), 99.75% (95% CI, 99.65-99.85), and 99.57% (95% CI, 99.11-100), respectively. Of note, for the HEAR<2, negative likelihood ratio was 0.07 (95% CI, 0.02-0.12). In the prehospital, at the HEAR<4 cutoff, the pooled sensitivity and NPV were 85.01% (95% CI, 80.56-89.47) and 91.48% (95% CI, 87.10-95.87), respectively. This study showed that in the ED, the HEAR score<2 can be used for an early discharge strategy. Currently, this score cannot be recommended in prehospital setting. Prospero (CRD42021273710).
参考来源
- Khaleghi Rad M, Pirmoradi MM, Doosti-Irani A, et al. The performance of HEAR score for identification of low-risk chest pain: a systematic review and meta-analysis. Eur J Emerg Med. 2022. PMID: 35446265. doi:10.1097/MEJ.0000000000000921
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。